Press Releases

Webcast
First Quarter 2019 Results Conference Call (Live)
Thursday, May 02, 2019 4:30 pm EDT
Date Title
04/18/19
Summary ToggleT2 Biosystems Announces 2019 First Quarter Financial and Operational Results Release and Conference Call Date Printer Friendly Version LEXINGTON, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it will release its 2019 first quarter financial and operational
04/09/19
Summary ToggleT2 Biosystems and Clinicians to Share Clinical Data in Integrated Symposium and Poster Presentations at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Printer Friendly Version Data will highlight how direct-from-whole blood innovations—the T2Bacteria, T2Candida and T2Resistance panels—positively impact patients with bloodstream infections LEXINGTON, Mass. , April 09, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), an emerging leader in the development of
04/08/19
Summary ToggleT2 Biosystems Reports Granting of Inducement Awards Printer Friendly Version LEXINGTON, Mass. , April 08, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on March 15, 2019 it issued inducement awards to seven
04/03/19
Summary ToggleT2 Biosystems to Present at the 18th Annual Needham Healthcare Conference Printer Friendly Version LEXINGTON, Mass. , April 03, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John Sprague , chief financial officer, is scheduled to
03/07/19
Summary ToggleT2 Biosystems Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Printer Friendly Version Secured 14 New Instrument Contracts in the Fourth Quarter and 39 total New Instrument Contracts in 2018 that are expected to drive growth in Recurring Test Revenue Confirms Guidance of a Doubling of Revenue in 2019; Provides Guidance of Securing 70 – 80 T2Dx Instruments Contracts in 2019 LEXINGTON,
02/27/19
Summary ToggleFDA Grants T2 Biosystems Breakthrough Device Designation for the T2Resistance™ Panel; Expected Availability through CE Mark in 2019 Printer Friendly Version New, expanded panel detects gram-negative and gram-positive resistance genes to help combat antimicrobial resistant bloodstream infections LEXINGTON, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- The FDA has granted T2 Biosystems , Inc. (NASDAQ:TTOO) “Breakthrough Device” designation for the
02/21/19
Summary ToggleT2 Biosystems to Present at the 8th Annual SVB Leerink Global Healthcare Conference Printer Friendly Version LEXINGTON, Mass. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough , president and chief executive officer, is
02/20/19
Summary ToggleT2 Biosystems Announces 2018 Fourth Quarter and Full Year Financial and Operational Results Release and Conference Call Date Printer Friendly Version LEXINGTON, Mass. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it will release its 2018 fourth quarter and full year
02/20/19
Summary ToggleFast Company Names T2Biosystems One of the World’s Most Innovative Companies – For Battling Sepsis in Hours not Days Printer Friendly Version Company ranked among Top Ten Most Innovative Companies in Biotech on annual list of organizations transforming industries and shaping society LEXINGTON, Mass. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for
02/07/19
Summary ToggleT2 Biosystems Reports Granting of Inducement Awards Printer Friendly Version LEXINGTON, Mass. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on February 1, 2019 it issued inducement awards to four